Drug Profile
Research programme: kynurenine metabolism inhibitors - Kymo Therapeutics
Alternative Names: KMO inhibitorsLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Metabrain Research
- Class
- Mechanism of Action Kynurenine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Metabolic-disorders in France
- 06 Nov 2016 Metabrain Research and Medicxi agree to co-develop kynurenine metabolism inhibitors in France for Metabolic disorders
- 06 Oct 2016 Early research in Metabolic disorders in France before October 2016